The inflammatory microenvironment in MDS

Cellular and Molecular Life Sciences

Volumn 72, Issue 10, 2015, Pages 1959-1966

  Yang, Lili ^a,b   Qian, Yaqin ^a,b   Eksioglu, Erika ^c   Epling Burnette, Pearlie K ^c   Wei, Sheng ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Immunosuppression; Inflammation; Innate immunity; Microenvironment; Myelodysplastic syndromes (MDS); Myeloid derived suppressor cells (MDSC); Stromal cells

Indexed keywords

CYTOKINE;

CLONAL EVOLUTION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT;

CELLULAR MICROENVIRONMENT; CLONAL EVOLUTION; CYTOKINES; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84931833143     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-1846-x     Document Type: Article

References (84)

1. Virdis A, Dell'Agnello U, Taddei S (2014) Impact of inflammation on vascular disease in hypertension. Maturitas 78(3):179-183
2. Wang YH, Liu YJ (2009) Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy 39(6):798-806
3. Chen X et al (2013) Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest 123(11):4595-4611
4. Ueda Y, Kondo M, Kelsoe G (2005) Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 201(11):1771-1780
5. Ganan-Gomez I et al (2014) Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-kappaB activation and enhances erythroid differentiation arrest. PLoS One 9(4):e93404
6. Balin SJ et al (2011) Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. Arch Dermatol 147(3):331-335
7. Mekinian A et al (2014) Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine (Baltimore) 93(1):1-10
8. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162-174
9. Kusmartsev S, Gabrilovich DI (2006) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55(3):237-245
10. Vogl T et al (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13(9):1042-1049
11. Ehrchen JM et al (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86(3):557-566
12. Sade-Feldman M et al (2013) Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38(3):541-554
13. Bouchliou I et al (2011) Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. Clin Immunol 139(3):350-359
14. Kordasti SY et al (2009) IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 145(1):64-72
15. Mailloux AW, Epling-Burnette PK (2013) Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology 2(2):e22654
16. Mailloux AW et al (2012) Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 189(6):3198-3208
17. Zou JX et al (2009) Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 23(7):1288-1296
18. Kordasti SY et al (2007) CD4+ CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 110(3):847-850
19. Sloand EM et al (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106(3):841-851
20. Benesch M et al (2003) Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 17(12):2460-2466
21. Kochenderfer JN et al (2002) Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100(10):3639-3645
22. Epling-Burnette PK et al (2007) Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 109(11):4816-4824
23. Epling-Burnette PK et al (2007) Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 21(4):659-667
24. Sloand EM, Rezvani K (2008) The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45(1):39-48
25. Olnes MJ, Sloand EM (2011) Targeting immune dysregulation in myelodysplastic syndromes. JAMA 305(8):814-819
26. Raaijmakers MH (2011) Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 96(7):1041-1048
27. Raaijmakers MH et al (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464(7290):852-857
28. Flores-Figueroa E et al (2005) Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 29(2):215-224
29. Flores-Figueroa E et al (2008) Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 32(9):1407-1416
30. Geyh S et al (2013) Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27(9):1841-1851
31. Zhao ZG et al (2012) Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett 317(2):136-143
32. Zhao Z et al (2012) The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes. PLoS One 7(9):e45675
33. Campioni D et al (2006) Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica 91(3):364-368
34. Lopez-Villar O et al (2009) Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia 23(4):664-672
35. Varga G et al (2007) Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 13(4):311-319
36. Aanei CM et al (2012) Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev 21(10):1604-1615
37. Walkley CR et al (2007) A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129(6):1097-1110
38. Walkley CR et al (2007) Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129(6):1081-1095
39. Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66(9):4553-4557
40. Sneddon JB, Werb Z (2007) Location, location, location: the cancer stem cell niche. Cell Stem Cell 1(6):607-611
41. Serio B et al (2014) Immunological derangement in hypocellular myelodysplastic syndromes. Transl Med UniSa 8:31-42
42. Li X et al (2010) The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 116(13):2304-2314
43. da Costa SV et al (2010) The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes. Leuk Res 34(4):507-512
44. Navas T et al (2008) Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma 49(10):1963-1975
45. Fessenden JD et al (2001) Ryanodine receptor point mutant E4032A reveals an allosteric interaction with ryanodine. Proc Natl Acad Sci USA 98(5):2865-2870
46. Wetzler M et al (1995) Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res 19(1):23-34
47. Weimar IS et al (1998) Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells. Leukemia 12(8):1195-1203
48. Marcondes AM et al (2008) Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 105(8):2865-2870
49. Selleri C et al (2002) Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 95(9):1911-1922
50. Sato T et al (1995) Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. Blood 86(9):3373-3380
51. Navas TA et al (2006) Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108(13):4170-4177
52. Sokol L et al (2013) Randomized, dose-escalation study of the p38alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 27(4):977-980
53. Bar M et al (2008) Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression. Transl Oncogenomics 3:137-149
54. Chen G et al (2004) Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 104(13):4210-4218
55. Maratheftis CI et al (2007) Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 13(4):1154-1160
56. Wei Y et al (2013) Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27(9):1832-1840
57. Dimicoli S et al (2013) Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One 8(8):e71120
58. Rhyasen GW et al (2013) Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24(1):90-104
59. Rhyasen GW, Bolanos L, Starczynowski DT (2013) Differential IRAK signaling in hematologic malignancies. Exp Hematol 41(12):1005-1007
60. Hofmann WK et al (2002) Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100(10):3553-3560
61. Gondek LP et al (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111(3):1534-1542
62. Starczynowski DT et al (2008) High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 112(8):3412-3424
63. Fang J et al (2012) Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 120(4):858-867
64. Starczynowski DT et al (2010) Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 16(1):49-58
65. Boldin MP et al (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208(6):1189-1201
66. Zhao JL et al (2011) NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 108(22):9184-9189
67. Fang J et al (2014) Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-kappaB gene network. Cell Rep 8(5):1328-1338
68. Kerbauy DM et al (2005) NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 106(12):3917-3925
69. Fabre C et al (2007) NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26(28):4071-4083
70. Pyatt DW et al (1999) An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood 93(10):3302-3308
71. Wei Y et al (2013) Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 27(11):2177-2186
72. Rupec RA et al (2005) Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity 22(4):479-491
73. Starczynowski DT, Karsan A (2010) Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am 24(2):343-359
74. Sloand EM et al (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26(15):2505-2511
75. Lim ZY et al (2007) Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21(7):1436-1441
76. Stadler M et al (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18(3):460-465
77. Steensma DP et al (2003) Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101(6):2156-2158
78. List A et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14):1456-1465
79. Fenaux P et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223-232
80. Deeg HJ et al (2002) Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 16(2):162-164
81. Raza A et al (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98(4):958-965
82. Deeg HJ et al (2004) Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 28(11):1177-1180
83. Scott BL et al (2010) Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol 149(5):706-710
84. Jaiswal S et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488-2498